Skip to main content
. 2019 Feb 7;10(4):607–623. doi: 10.1111/1759-7714.12971

Figure 5.

Figure 5

Forest plots of hazard ratio (HR) of overall survival (OS); HR of progression‐free survival (PFS) associated with (a) immune checkpoint inhibitors (ICIs) ± chemotherapy versus chemotherapy ± placebo or (b) ICIs versus chemotherapy in first line treatment of non‐small cell lung cancer (NSCLC) population with high tumor‐mutational burden (TMB). Chemo, chemotherapy; CI, confidence interval; ORR, overall response rate; Placbo, placebo.